FORTELYZIN IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION
Sergey S. Markin, Andrey M. Semenov, E. V. Arzamascev, В. А. Марков, Е. В. Вышлов, Aleksey Aleksandrovich Nizov, С Б Аксентьев, Э. А. Пономарев, Г. Н. Гридасов, Petr A. Lebedev, О. Л. Барбараш, В. В. Кашталап · Medical academic journal · 2012
Fortelyzin is new fibrinselective thrombolytic agent, gene-modified staphylokinase. This clinical trial showed that Fortelyzin and Actilyse are comparative effective thrombolytic by rate achieve TIMI grade reperfusion in patients with acute myocardial infarction. In the Actilyse patients group the fibrinogen level decreased more intensive then in Fortelyzin group. The safety was similar in both groups.